Molecular Biomarkers for Neurodegeneration
Dr. Rivka Dikstein of the Department of Biomolecular Sciences is investigating the “checks and balances” that control how our genetic code is transformed into functional proteins. While fascinating from the point of view of basic science, Dr. Dikstein’s research also has practical, biomedical significance. Among her recent accomplishments, she has positively identified 150 compounds with clinical potential for preventing the binding of molecular factors associated with the onset of neurodegeneration. This work has significance for the development of future treatments for three currently incurable neurodegenerative diseases: Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).